Advertisement

Children’s Oncology Group (COG) Trials for Retinoblastoma

  • Dan S. GombosEmail author
  • Anna T. Meadows
  • Murali Chintagumpala
  • Ira J. Dunkel
  • Debra Friedman
  • Julie Ann Stoner
  • Rima Jubran
  • Judith Grob Villablanca
Chapter

Abstract

For the past 30 years, retinoblastoma, a tumor that occurs in only 3 % of children with cancer, has been the subject of extensive molecular biologic research. However, apart from a short period in the 1970s, retinoblastoma has not been studied by any of the pediatric cooperative groups. The past decade has witnessed significant multidisciplinary prospective clinical and biologic studies of this rare pediatric neoplasm. The Children’s Oncology Group (COG) has successfully opened four clinical trials with a fifth recently approved. This chapter will review these ongoing prospective multicenter trials.

Keywords

Stem Cell Rescue Bone Marrow Disease Optic Nerve Involvement Bilateral Retinoblastoma Intraocular Retinoblastoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer. 2005;5:91–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18:12–7.PubMedGoogle Scholar
  3. 3.
    Murphree AL, Villablanca JG, Deegan 3rd WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133:657–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Knudson AG. The role of retinoblastoma in understanding human cancer. In: Singh AD, Damato BE, Pe’er J, Murphree AL, Perry JD, editors. Clinical ophthalmic oncology. Philadelphia: Saunders-Elsevier; 2007, Chapter 65.Google Scholar
  6. 6.
    Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41–53.CrossRefGoogle Scholar
  7. 7.
    Schvartzman E, Chantada G, Fandino A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996;14:1532–6.PubMedGoogle Scholar
  8. 8.
    Messmer EP, Heinrich T, Hopping W, et al. Risk factors for metastases in patients with retinoblastoma. Ophthalmology. 1991;98:136–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544–8.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119:41–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Woolson RF. Rank tests and a one-sample logrank test for comparing observed survival data to a standard population. Biometrics. 1981;37:687–96.CrossRefGoogle Scholar
  15. 15.
    Jennison C, Turnbull BW. Group sequential methods with application to clinical trials. Boca Raton: Chapman and Hall/CRC; 2000.Google Scholar
  16. 16.
    Anteby I, Ramu N, Gradstein L, et al. Ocular and orbital complications following the treatment of retinoblastoma. Eur J Ophthalmol. 1998;8:106–11.PubMedGoogle Scholar
  17. 17.
    Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol. 1997;15:1183–9.PubMedGoogle Scholar
  18. 18.
    Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23:2272–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21:2019–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569–77.PubMedGoogle Scholar
  22. 22.
    Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Chan HSL, Heon E, Budning A, et al. Improvement of the cure rate of intraocular retinoblastoma without significantly increasing toxicity with higher dose carboplatin-teniposide in a cyclosporine multidrug reversal regimen. In: Proceedings 10th International Symposium on Retinoblastoma. 2001.Google Scholar
  24. 24.
    Villablanca JG, Atchaneeyasakul L, Murphree AL. Clinical outcome of Group V eyes treated with cyclosporin A/carboplatin/etoposide/vincristine. In: Proceedings 10th International Symposium on Retinoblastoma. 2001.Google Scholar
  25. 25.
    Villablanca JG, Jubran RF, Murphree LA. Phase I study of subtenon carboplatin with systemic high dose carboplatin/etoposide/vincristine for eyes with disseminated intraocular retinoblastoma. In: Proceedings 10th International Symposium on Retinoblastoma. 2001.Google Scholar
  26. 26.
    Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Chantada G, Fandino A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40:15–161.CrossRefGoogle Scholar
  28. 28.
    Antoneli CB, Steinhorst F, de Cassia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997;33:2368–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89:2117–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Kremens B, Wieland R, Reinhard H, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. 2003;31:281–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology. 2003;110:1237–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Jubran RF, Erdreich-Epstein A, Butturini A, et al. Approaches to treatment for extraocular retinoblastoma: Children’s Hospital Los Angeles experience. J Pediatr Hematol Oncol. 2004;26:31–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35:763–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients. Cancer. 1994;74:722–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.PubMedGoogle Scholar
  37. 37.
    Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9:69–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–404. 1404.e1.PubMedCrossRefGoogle Scholar
  39. 39.
    Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Dan S. Gombos
    • 1
    Email author
  • Anna T. Meadows
    • 2
  • Murali Chintagumpala
    • 3
  • Ira J. Dunkel
    • 4
  • Debra Friedman
    • 5
  • Julie Ann Stoner
    • 6
  • Rima Jubran
    • 7
  • Judith Grob Villablanca
    • 7
  1. 1.The Retinoblastoma Center of Houston, MD Anderson Cancer Center/Texas Children’s Hospital, Baylor College of Medicine/Methodist Hospital Research InstituteHoustonUSA
  2. 2.The Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  3. 3.Texas Children’s Cancer Center at Baylor CollegeHoustonUSA
  4. 4.Memorial Sloan Kettering Cancer CenterNew YorkUSA
  5. 5.Division of Hematology-OncologyVanderbilt University School of MediciNENashvilleUSA
  6. 6.University of Nebraska Medical CenterOmahaUSA
  7. 7.Children’s Hospital of Los AngelesLos AngelesUSA

Personalised recommendations